New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
07:06 EDTCBRX, MRKColumbia Laboratories CEO sees Q3 revenues improving
Columbia Laboratories (CBRX) CEO stated, "The routine license renewal by Merck (MRK) Serono for one of its high-volume, high-margin markets is expected to be complete in 2H14, whereupon normal shipments will then resume at the beginning of 2015. The new license will be in place for five years, thereby restoring the predictability of this long-term revenue stream. In the interim, Merck Serono placed an order with us as part of a one-time exception during the renewal process. The order will be shipped in Q3 and benefit that quarter's revenues. In terms of the services business, we expect a sequential improvement in Q3 revenues due to successful recent business development activities and customer interest in our comprehensive suite of advanced technologies."
News For CBRX;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 28, 2014
07:27 EDTMRKFDA PDUFA Date for Merck's MK-3475 is October 28, 2014
Subscribe for More Information
07:16 EDTMRKInvestors overlooking Merck positive points, says SunTrust
Subscribe for More Information
07:10 EDTCBRXColumbia Laboratories sees 2014 revenue growth 14%-16%
Subscribe for More Information
07:09 EDTCBRXColumbia Laboratories reports Q3 EPS 34c, one estimate 12c
Subscribe for More Information
October 27, 2014
20:54 EDTMRKLeerink's major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
16:36 EDTMRKOn The Fly: Closing Wrap
Subscribe for More Information
09:37 EDTMRKMerck slips lower after results, levels to watch
Subscribe for More Information
08:30 EDTMRKMerck sees FY14 gross margin slightly lower vs. FY13
Subscribe for More Information
07:29 EDTMRKWorldwide Business Research to hold a conference
ProcureCon Pharma 2014 is being held in Philadelphia on October 27-29.
07:06 EDTMRKMerck reports Q3 Pharmaceutical sales down 4% to $9.13B
Subscribe for More Information
07:03 EDTMRKMerck narrows 2014 EPS outlook to $3.46-$3.50, consensus $3.47
Now sees 2014 revenue $42.4B-$42.8B, consensus $42.55B.
07:01 EDTMRKMerck reports Q3 EPS ex-items 90c, consensus 88c
Subscribe for More Information
06:46 EDTMRKMerck granted Breakthrough Therapy Designation for KEYTRUDA by FDA
Subscribe for More Information
October 24, 2014
13:35 EDTMRKMerck weekly volatility elevated into Q3 and outlook
Subscribe for More Information
October 22, 2014
07:35 EDTMRKCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
October 20, 2014
08:06 EDTMRKMerck, Sanofi unit announce pediatric hexavalent vaccine BLA
Subscribe for More Information
07:34 EDTMRKAdvaxis names Mauro Chief Medical Officer
Advaxis (ADXS) announced that it has appointed David Mauro, as executive vice president, Chief Medical Officer Mauro most recently served as executive director, section head oncology clinical development at Merck (MRK). In connection with his appointment, Mauro received a one-time inducement award of 165K restricted shares, of which 55K are fully vested and as of the grant date. The remaining shares vest annually over a two-year period.
07:19 EDTMRKIBC Life Sciences to hold a conference
Subscribe for More Information
07:11 EDTMRKAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
October 17, 2014
07:58 EDTMRKDeutsche Bank specialty pharma analyst holds analyst/industry conference call
Specialty Pharmaceuticals Analyst Gilbert provides of preview of The Improved Reduction of Outcomes: Vytorin Efficacy Internal Study (IMPROVE-IT) on an Analyst/Industry conference call to be held on October 17 at 10 am.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use